The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment

Journal of Clinical Microbiology

Volumn 52, Issue 8, 2014, Pages 3064-3067

  Honeyborne, Isobella ^a   Mtafya, Bariki ^b   Phillips, Patrick P J ^a   Hoelscher, Michael ^c,d   Ntinginya, Elias N ^b   Kohlenberg, Anke ^b   Rachow, Andrea ^c,d   Rojas Ponce, Gabriel ^b   McHugh, Timothy D ^a   Heinrich, Norbert ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Partner Site Munich   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT; AGAR; CULTURE MEDIUM;

ARTICLE; ASSAY; BACTERIAL LOAD; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE TECHNIQUE; HUMAN; INTERMETHOD COMPARISON; LIQUID CULTURE; MOLECULAR BACTERIAL LOAD ASSAY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SOLID AGAR CULTURE; SPUTUM; TUBERCULOSIS; CHEMISTRY; COMPARATIVE STUDY; CULTURE MEDIUM; DRUG EFFECTS; EVALUATION STUDY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MOLECULAR DIAGNOSIS; PROCEDURES;

AGAR; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CULTURE MEDIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS;

EID: 84905252679     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01128-14     Document Type: Article

References (18)

1. Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Maritz JS, Fourie PB. 2003. Early bactericidal activity of antituberculosis agents. Expert Rev. Anti Infect. Ther. 1:141-155. http://dx.doi.org/10.1586/ 14787210.1.1.141. (Pubitemid 38735735)
2. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. 18 August 2011. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin. Microbiol. Infect. http://dx.doi.org/10.1111/j. 1469-0691.2011.03626.x.
3. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. 2004. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J. Clin. Microbiol. 42:2321-2325. http://dx.doi.org/10.1128/JCM.42.5.2321-2325.2004. (Pubitemid 38637876)
4. Tyrrell FC, Budnick GE, Elliott T, Gillim-Ross L, Hildred MV, Mahlmeister P, Parrish N, Pentella M, Vanneste J, Wang YF, Starks AM. 2012. Probability of negative Mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systems. J. Clin. Microbiol. 50:3275-3282. http://dx.doi.org/10.1128/JCM.01225- 12.
5. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. 2010. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am. J. Respir. Crit. Care Med. 181:174-180. http://dx.doi.org/10. 1164/rccm.200905-0661OC.
6. Shleeva MO, Bagramyan K, Telkov MV, Mukamolova GV, Young M, Kell DB, Kaprelyants AS. 2002. Formation and resuscitation of "nonculturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 148:1581-1591. (Pubitemid 34567236)
7. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, Walzl G, Gillespie SH. 2011. Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J. Clin. Microbiol. 49:3905-3911. http://dx.doi.org/10.1128/JCM. 00547-11.
8. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43:717-731. http://dx.doi.org/10. 1046/j.1365-2958.2002.02779.x. (Pubitemid 34597265)
9. Miles AA, Misra SS, Irwin JO. 1938. The estimation of the bactericidal power of the blood. J. Hyg. (Lond.) 38:732-749. http://dx.doi.org/10.1017/ S002217240001158X.
10. Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A, Boom WH, Eisenach KD. 2010. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J. Clin. Microbiol. 48:46-51. http://dx.doi.org/10.1128/JCM.01526-09.
11. Davies GR, Brindle R, Khoo SH, Aarons LJ. 2006. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob. Agents Chemother. 50:3154-3156. http://dx.doi.org/10.1128/AAC.00774-05. (Pubitemid 44396425)
12. Brindle R, Odhiambo J, Mitchison D. 2001. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm. Med. 1:2. http://dx.doi.org/10.1186/1471-2466-1-2.
13. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138. (Pubitemid 351212403)
14. Gillespie SH, Gosling RD, Charalambous BM. 2002. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Am. J. Respir. Crit. Care Med. 166:31-35. http://dx.doi.org/10.1164/rccm.2112077. (Pubitemid 34693959)
15. Jindani A, Dore CJ, Mitchison DA. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354. http://dx.doi.org/10.1164/rccm.200210-1125OC. (Pubitemid 36609718)
16. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986-993. http://dx.doi.org/10.1016/S0140-6736(12)61080-0.
17. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M, Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). 2013. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir. Med. 1:462-470. http://dx.doi.org/10.1016/S2213-2600(13)70119-X.
18. Kayigire XA, Friedrich SO, Venter A, Dawson R, Gillespie SH, Boeree MJ, Heinrich N, Hoelscher M, Diacon AH, Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics. 2013. Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J. Clin. Microbiol. 51:1894-1898. http://dx.doi.org/10. 1128/JCM.03290-12.